

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
A, part 2 (i)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
A, part 2 (ii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
A, part 2 (iii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>
C	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="text" value="2013"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: 27 November 2014

State Party to the Convention: Norway

Date of ratification/accession to the Convention:

National point of contact: Åshild Kjøl

Ashild.Kjol@mfa.no

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and
- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

At the Third Review Conference it was agreed that States Parties continue to implement the following:

"Exchange of data, including name, location, scope and general description of activities, on research centres and laboratories that meet very high national or international safety standards established for handling, for permitted purposes, biological materials that pose a high individual and community risk or specialize in permitted biological activities directly related to the Convention."

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

Data should be provided by States Parties on each facility, within their territory or under their jurisdiction or control anywhere, which has any maximum containment laboratories meeting those criteria for such maximum containment laboratories as specified in the latest edition of the WHO¹ Laboratory Biosafety Manual and/or OIE² Terrestrial Manual or other equivalent guidelines adopted by relevant international organisations, such as those designated as biosafety level 4 (BL4, BSL4 or P4) or equivalent standards.

States Parties that do not possess a facility meeting criteria for such maximum containment should continue to Form A, part 1 (ii).

Form A, part 1 (i)

Exchange of data on research centres and laboratories³

- | | |
|--|--|
| 1. Name(s) of facility ⁴ | Institute of Microbiology,
Armed Forces Medical Services |
| 2. Responsible public or private organization or company | Ministry of Defence |
| 3. Location and postal address | Lovisenberggaten 8, N-0456 Oslo.
This location is within the confinement of the Norwegian Institute of Public Health.
Postal address: P.O. Box 4302 Nydalen, N-0402 Oslo, Norway |

¹ World Health Organization

² World Organization for Animal Health

³ The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

⁴ For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Wholly financed by the Ministry of Defence

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

No BL-4

6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Bacterial groups:

Bacillus, chlamydia, francisella, legionella, staphylococcus

Viruses: Hantavirus

Toxins from:

Bacillus, clostridium, shigella, staphylococcus, yersina

Activities:

Diagnostics

Transmission studies

Epidemiology

Immunology

Form A, part 1 (ii)

If no BSL4 facility is declared in Form A, part 1 (i), indicate the highest biosafety level implemented in facilities handling biological agents⁶ on a State Party's territory:

Biosafety level 3 ⁷	<u>yes</u>
Biosafety level 2 ⁸ (if applicable)	yes / no

Any additional relevant information as appropriate:

One unit, 175 m²

⁵ In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.

⁶ Microorganisms pathogenic to humans and/or animals

⁷ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

⁸ In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated;
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on

pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

2. State the total funding for each programme and its source.

Within the institute's annual budget.

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Institute of Microbiology, Armed Forces Medical Services, Oslo, Norway

2. Where is it located (include both address and geographical location)?

P.O. Box 4302 Nydalen, N-0402 Oslo

Location: Lovisenberggaten 8, N-0456 Oslo

3. Floor area of laboratory areas by containment level:

BL2 175 (sqM)

BL3 175 (sqM)

BL4 N/A

Total laboratory floor area 350 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel 7

(ii) Division of personnel:

Military 1

Civilian 6

(iii) Division of personnel by category:

Scientists 2

Engineers 3

Technicians 2

Administrative and support staff 0

(iv) List the scientific disciplines represented in the scientific/engineering staff.

Human and veterinarian infection

(v) Are contractor staff working in the facility? If so, provide an approximate number.

No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

100% by the Ministry of Defence

(vii) What are the funding levels for the following programme areas:

Research

Teaching

Field studies

(viii) Briefly describe the publication policy of the facility:

Reviewed international scientific journals

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms⁹ and/or toxins studied, as well as outdoor studies of biological aerosols.

Diagnostic of bacterial toxins from bacillus, clostridium, shigella, staphylococcus, yersinia

⁹ Including viruses and prions.

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent¹⁰ is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by

¹⁰ It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.

toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern¹¹

There have been no unusual outbreaks, including human, animal and plant disease.

Notification on incidence of human disease

Disease	2005	2006**	2007	2008	2009	2010	2012	2013
Anthrax	0	0	0	0	0	0	0	0
AIDS	30	11	9	18	16	22	25	29
Botulism	5	2	0	0	0	1	0	8
Brucellosis	0	0	0	0	0	2	4	2
Campylobacteriosis	2583	1100	2834	2876	2851	2673	2933	3291
Cholera	0	0	1	0	0	0	0	0
Creutzfeldt-Jacobs	6	0	5	6	10	12	0	0
Diphtheria	0	0	0	4	0	0	0	0
Enteropathogenic E. coli	68	74	113	157	477	366	373	281
Giardiasis, native and imported	390	62	290	270	307	262	179	227
Gonorrhoea	280	142	238	292	263	405	443	506
Hemorrhagic fever	0	0	0	0	0	0	0	0
Hepatitis A	51	13	29	50	40	46	40	51
Hepatitis B, disease	141	123	118	98	53	27	46	30
Hepatitis B, carrier	550	33	513	675	836	745	661	710
Hepatitis C, disease	32	46	150	3446	2351	1811	1526	1308
HIV infection	220	91	248	299	274	256	242	233
Japanese encephalitis	0	0	0	0	0	0	0	0
Legionellosis, native and imported	86	11	35	41	35	48	23	40
Leprosy	0	0	0	0	0	0	0	1
Lyme borreliosis	267	228	328	347	278	289	255	315
Malaria, imported	35	0	27	30	34	37	37	87
Measles	0	0	20	4	2	3	4	8

¹¹ See paragraph 2 of the chapeau to Confidence-Building Measure B.

Meningitis, bacterial	37	26	30	36	44	39	24	27
Mumps	8	14	22	16	2	12	30	35
Nephropathia epidemica	64	19	76	50	21	21	13	19
Pertussis	875	1110	5374	3893	5562	3567	4248	2608
Plague	0	0	0	0	0	0	0	0
Pneumococchemia	1035	866	958	856	802	747	626	620
Poliomyelitis	0	0	0	0	0	0	0	0
Rabies	0	0	0	0	0	0	0	0
Relapsing fever	0	0	0	0	0	0	0	0
Rubella	1	0	0	1	0	0	1	3
Salmonella enteritis	1412	385	1649	1941	1235	1366	1372	1382
Shigellosis	160	26	148	134	152	132	77	104
Streptococcus group A invasive disease	242	127	132	172	171	161	137	183
Streptococcus group B invasive disease	151	162	184	178	174	159	204	201
Syphilis	25	47	61	52	76	95	109	185
Tetanus	0	0	2	2	1	0	1	0
Tularemia	17	7	49	66	13	33	50	28
TBC			308	327	350	351	383	
Typhoid fever	22	4	29	16	11	16	13	10
Yersiniosis	196	99	71	50	60	52	43	55
Echinococcosis				2	0	1	0	2
Encephalitis				134	139	171	270	250
Rickettsial spotted fever				0	0	0	0	0
Yellow fever				0	0	0	0	0
Listeriosis				34	31	22	30	21
MRSA – staphylococcal infection				348	410	433	575	659

MRSA – carrier state				306	373	469	622	823
Paratyphoid fever				17	17	18	7	16
Sars				0	0	0	0	0
Haemophilus influenzae septicaemia				75	72	90	78	86
Trichinosis				0	0	0	0	0
Vancomycin-resistant enterococcal infection				6	6	50	166	
Influenzae A (H1N1)					12490	103	*	

There was no unnatural outbreak in 2013. Year-to-year variations are accepted as normal values.

1. Time of cognizance of the outbreak _____
2. Location and approximate area affected _____
3. Type of disease/intoxication _____
4. Suspected source of disease/intoxication _____
5. Possible causative agent(s) _____
6. Main characteristics of systems _____
7. Detailed symptoms, when applicable **Nothing to declare from Norway**
 - respiratory _____
 - circulatory _____
 - neurological/behavioural _____
 - intestinal _____
 - dermatological _____
 - nephrological _____
 - other _____
8. Deviation(s) from the normal pattern as regards
 - type _____
 - development _____
 - place of occurrence _____

- time of occurrence _____
- symptoms _____
- virulence pattern _____
- drug resistance pattern _____
- agent(s) difficult to diagnose _____
- presence of unusual vectors _____
- other _____
- 9. Approximate number of primary cases _____
- 10. Approximate number of total cases _____
- 11. Number of deaths _____
- 12. Development of the outbreak _____
- 13. Measures taken _____

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Confidence-Building Measure "D"

(Deleted)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

- (a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;

(b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;

(c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures ¹²	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	No	No
(b) Exports of micro-organisms ¹³ and toxins	Yes	Yes	No	No
(c) Imports of micro-organisms ¹¹ and toxins	Yes	Yes	No	No
(d) Biosafety ¹⁴ and biosecurity ¹⁵	Yes/No	Yes/No	Yes/No	Yes/No

¹² Including guidelines.

¹³ Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

¹⁴ In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.

¹⁵ In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

2. Past offensive biological research and development programmes:
 - No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:
 - No

 - Period(s) of activities

 - Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Re 3: Work on human and animal diseases, but nothing bearing on what is understood as a biological programme related to defence activities. All BTWC-related work that has been performed in Norway by military, public health, university, or other facilities, is published in open international scientific papers.

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

Alpharma
Located at N-7893 Overhalla.
Produces large amounts of various fish vaccines.

The National Veterinary Institute
Ullevålsveien 68, N-0454 Oslo
Small-scale production of autogenous vaccines against various infections in animals.

The Norwegian Institute of Public Health
Postboks 4404 Nydalen, N-0403
Have ready vaccine production facilities. Possible future areas of production is influenza vaccine, and vaccine against *Neisseria meningitidis* group B infection.

This list of vaccine production facilities is unchanged for the last seven years.